Patent · US Active

Prodrug anti-cancer therapy

US8609813B2 · kind B2 · utility

0Cited by
2References
3Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 22, 2010
Grant dateDec 17, 2013
Priority date—
Expiry dateOct 31, 2031

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N9/1205
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compositions and methods for inhibiting the growth of cancer cells are provided. The cancer cells, the growth of which is inhibited, have constitutively active Abl tyrosine kinase activity due to a t(9;22)(q34;q11) translocation which results in expression of a chimeric Bcr-Abl protein which has constitutively active Abl tyrosine kinase activity that is believed to play an important role in leukemogenesis. The compositions include a modified protein kinase C(PKC) which has an Abl tyrosine kinase target motif. The methods involve administering the modified PCK to an individual to inhibit the growth of cancer cells that have Abl tyrosine kinase activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.